StocksMedium•28 September 2026•
1 min read
Palatin Technologies Narrows Annual Loss and Pivots to Obesity Pipeline
Key Facts
1Palatin Technologies reported significant revenue improvement and a narrowed net loss for fiscal year 2026.
2The company is focusing on MC4R therapies for rare obesity disorders with clinical studies planned for 2027 and 2028.
3The company faces going-concern risks and will require additional financing to sustain operations.
Palatin Technologies reported significant revenue improvement and a narrowed net loss for fiscal year 2026. Investing.com Canada reported that the company is focusing on developing MC4R therapies for rare obesity disorders, with clinical studies planned for 2027 and 2028.
The company faces going-concern risks and will require additional financing to sustain its operations despite the progress in its drug pipeline. PTN closed at $10.1 on September 25, 2026, having traded between a low of $9.5 and a high of $10.35 during that session.